<DOC>
	<DOCNO>NCT00533299</DOCNO>
	<brief_summary>The current standard recurrent , persistent metastatic cisplatin-resistant ovarian cancer palliative chemotherapy either topotecan , liposomal doxorubicin gemcitabine , however , result need improve . Epigenetic aberration play important role cancer progression silence growth regulatory gene evidence inhibitor DNA methylation HDAC inhibition synergize cytotoxicity chemotherapy . Objective . To determine superiority epigenetic therapy hydralazine valproate plus topotecan placebo plus topotecan upon progression-free survival . Hypothesis . Hydralazine magnesium valproate associate topotecan increase progression-free survival 6 9 month compare regimen chemotherapy plus placebo .</brief_summary>
	<brief_title>Hydralazine Valproate Ovarian Cancer</brief_title>
	<detailed_description>Randomized , double-blind phase III trial . A total 211 patient ( alpha 0.5 , power 0.8 ) cisplatin-resistant recurrent persistent cancer randomize topotecan + placebo topotecan + hydralazine + valproate 6 course every 4 week . Patients receive oral dose hydralazine 182mg ( rapid ) 83mg ( slow ) accord acetylator phenotype single daily dose magnesium valproate oral dose 40mg/Kg t.i.d . Both drug slow-release formulation . Experimental drug placebo start seven day day 1 chemotherapy end sixth course .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<mesh_term>Hydralazine</mesh_term>
	<criteria>Measurable evaluable disease ( evaluable accord CA125 criterion GCIG ) Cisplatin resistant ovarian cancer Persistent progression first line platinumbased chemotherapy Relapse within 6 month complete first line platinumbased chemotherapy Platinumsensitive disease fail second line therapy base platinum . Adequate organic function define : hemoglobin &gt; 10 g/L , leukocytes &gt; 4000/mm3 , platelet &gt; 100 000mm3 ; normal creatinine value creatinine clearance &gt; 60 mL/min ; total bilirubin &lt; 1.5 upper normal limit value History allergy hydralazine valproate ; Past present condition rheumatic disease , central nervous system disease , heart failure aortic stenosis postural hypotension diagnose physician ; Newly diagnose hypertension patient without pharmacological treatment allow long treatment include hydralazine . Previous use experimental drug ( hydralazine magnesium valproate ) well patient pregnant breastfeeding . Other exclusion criterion uncontrolled systemic disease infection .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Epigenetics , hydralazine , valproate , ovarian cancer</keyword>
</DOC>